Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

TLPH

Talphera Inc

Dec 13 • 04:00PM ET

0.6500

Dollar change -0.0071
Percentage change -1.08	%

Healthcare • Drug Manufacturers - Specialty & Generic • USA • NASD

Peers: LLY PFE MRK BMY JNJ GILD REGN AMGN VRTX BIIB

| Held by: VTI VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.68	Insider Own	2.27%	Shs Outstand	17.03M	Perf Week	-5.93%
Market Cap	10.95M	Forward P/E	-	EPS next Y	-0.77	Insider Trans	7.54%	Shs Float	16.64M	Perf Month	-26.97%
Income	-15.65M	PEG	-	EPS next Q	-0.17	Inst Own	29.78%	Short Float	0.25%	Perf Quarter	-26.14%
Sales	0.28M	P/S	39.11	EPS this Y	54.26%	Inst Trans	-6.13%	Short Ratio	0.42	Perf Half Y	-38.68%
Book/sh	0.57	P/B	1.15	EPS next Y	-29.66%	ROA	-70.64%	Short Interest	0.04M	Perf Year	-7.63%
Cash/sh	0.66	P/C	0.98	EPS next 5Y	-	ROE	-111.91%	52W Range	0.62 - 1.61	Perf YTD	-11.56%
Dividend Est.	-	P/FCF	-	EPS past 5Y	39.67%	ROI	-96.80%	52W High	-59.63%	Beta	0.23
Dividend TTM	-	Quick Ratio	4.42	Sales past 5Y	-0.99%	Gross Margin	65.84%	52W Low	5.69%	ATR (14)	0.07
Dividend Ex-Date	-	Current Ratio	4.42	EPS Y/Y TTM	69.54%	Oper. Margin	-5885.77%	RSI (14)	37.87	Volatility	10.05% 12.06%
Employees	15	Debt/Eq	0.68	Sales Y/Y TTM	-54.82%	Profit Margin	-5569.75%	Recom	1.00	Target Price	4.17
Option/Short	Yes / Yes	LT Debt/Eq	0.68	EPS Q/Q	-57.90%	Payout	-	Rel Volume	0.63	Prev Close	0.66
Sales Surprise	-	EPS Surprise	31.58%	Sales Q/Q	-100.00%	Earnings	Nov 13 AMC	Avg Volume	100.18K	Price	0.65
SMA20	-8.11%	SMA50	-20.75%	SMA200	-31.38%	Trades		Volume	62,967	Change	-1.08%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-20-20	Downgrade	Credit Suisse	Neutral → Underperform
Nov-11-19	Downgrade	Credit Suisse	Outperform → Neutral	$7 → $2
Aug-05-19	Resumed	Credit Suisse	Outperform
Jul-10-19	Resumed	Credit Suisse	Outperform
Apr-24-19	Resumed	B. Riley FBR	Buy	$6.50
Feb-15-19	Initiated	Credit Suisse	Outperform	$7
Oct-23-18	Initiated	B. Riley FBR	Buy	$9
Oct-13-17	Reiterated	RBC Capital Mkts	Outperform	$6 → $5
Oct-13-17	Downgrade	Jefferies	Buy → Hold
Jul-14-17	Resumed	Jefferies	Buy	$7
Sep-15-16	Reiterated	ROTH Capital	Buy	$11.25 → $15
Aug-05-16	Downgrade	Stifel	Buy → Hold
Oct-30-15	Upgrade	Jefferies	Hold → Buy
Oct-05-15	Reiterated	ROTH Capital	Buy	$8.50 → $10.50
Sep-02-15	Initiated	H.C. Wainwright	Buy	$8.50
Jul-10-15	Resumed	ROTH Capital	Buy	$7.50
May-06-15	Reiterated	Mizuho	Neutral	$5.50 → $3
May-05-15	Reiterated	RBC Capital Mkts	Outperform	$8 → $7
Mar-10-15	Reiterated	RBC Capital Mkts	Outperform	$12 → $8
Mar-09-15	Downgrade	Mizuho	Buy → Neutral	$14 → $5.59

Show Previous Ratings

Nov-24-24 07:27PM	Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors (PR Newswire)
Nov-14-24 02:14AM	Talphera Inc (TLPH) Q3 2024 Earnings Call Highlights: Strategic Advances and Financial Challenges (GuruFocus.com) -25.61%
Nov-13-24 04:05PM	Talphera Announces Third Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire)
Nov-06-24 04:05PM	Talphera to Host Third Quarter 2024 Financial Results and Corporate Update Call and Webcast on Wednesday, November 13, 2024 (PR Newswire)
Oct-08-24 04:54PM	Talphera to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit (PR Newswire)
04:15PM	Loading…
Sep-05-24 04:15PM	Talphera to Participate in the H.C. Wainwright 26th Annual Global Investment Conference (PR Newswire) +5.62%
Aug-19-24 08:30AM	Talphera Announces First Patient Enrolled in the Registrational Trial Evaluating Nafamostat for Anticoagulation of the Extracorporeal Circuit (PR Newswire)
Aug-14-24 04:01PM	Talphera Announces Second Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire) -5.49%
Aug-05-24 04:05PM	Talphera to Host Second Quarter 2024 Financial Results and Corporate Update Call and Webcast on Wednesday, August 14, 2024 (PR Newswire)
Jun-26-24 07:41AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace) +6.02%
Jun-20-24 07:28AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace) +5.88%
May-20-24 05:25PM	Talphera Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
May-16-24 05:45PM	Talphera to Participate at A.G.P. Virtual Healthcare Conference (PR Newswire) -5.35% -6.09%
May-14-24 08:56PM	TLPH Stock Earnings: Talphera Beats EPS for Q1 2024 (InvestorPlace) +19.12%
04:05PM	Talphera Announces First Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire)
04:15PM	Loading…
May-02-24 04:15PM	Talphera to Host First Quarter 2024 Financial Results Call and Webcast on Tuesday, May 14, 2024 (PR Newswire)
Mar-06-24 09:53PM	TLPH Stock Earnings: Talphera Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace) -10.63%
04:05PM	Talphera Announces Fourth Quarter 2023 Financial Results and Provides Corporate Update (PR Newswire)
Mar-01-24 07:30AM	Talphera Announces Reduction in Size of its Board of Directors from Ten to Seven Members (PR Newswire)
Feb-26-24 04:15PM	Talphera to Host Fourth Quarter and Full-Year 2023 Financial Results Call and Webcast on March 6, 2024 (PR Newswire)
Jan-18-24 08:30AM	Talphera Announces $26 Million Capital Commitment Through a Combination of a Non-Dilutive Royalty Monetization and Equity Offering (PR Newswire) +26.01%
Jan-09-24 09:05AM	AcelRx Announces Rebranding With Name Change to Talphera, Inc. (PR Newswire) +7.50%
Dec-12-23 08:30AM	AcelRx Pharmaceuticals Announces Publication of Study Evaluating Anticoagulation Practices for Continuous Renal Replacement Therapy in the United States (PR Newswire) -9.01%
Nov-09-23 11:06AM	AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Q3 2023 Earnings Call Transcript (Insider Monkey) -11.34%
Nov-08-23 05:22PM	AcelRx Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	AcelRx Reports Third Quarter 2023 Financial Results and Provides Corporate Update (PR Newswire)
Nov-07-23 04:05PM	AcelRx to Host KOL Panel Discussion on Current Anticoagulant Use in Dialysis and the Upcoming Niyad Clinical Study (PR Newswire)
Oct-26-23 04:30PM	AcelRx to Host Third Quarter 2023 Financial Results Call and Webcast on November 8, 2023 (PR Newswire)
Oct-03-23 08:30AM	AcelRx Receives IDE Approval for Niyad and Advances to a Single Registration Study (PR Newswire)
Sep-12-23 01:02PM	Insider Buying: CEO Vincent Angotti Acquires 10,000 Shares of AcelRx Pharmaceuticals Inc (GuruFocus.com) +12.80%
08:30AM	Loading…
Sep-06-23 08:30AM	AcelRx Pharmaceuticals to Participate in the H.C. Wainwright Annual Investment Conference (PR Newswire)
Aug-22-23 05:30PM	What Makes AcelRx Pharmaceuticals (ACRX) a New Buy Stock (Zacks)
Aug-13-23 05:33AM	AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-11-23 06:07AM	Q2 2023 AcelRx Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-10-23 05:30PM	AcelRx Pharmaceuticals (ACRX) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -5.46%
04:20PM	AcelRx Pharmaceuticals: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	AcelRx Reports Second Quarter 2023 Financial Results and Provides Corporate Update (PR Newswire)
Jul-27-23 04:05PM	AcelRx to Host Second Quarter 2023 Financial Results Call and Webcast on August 10, 2023 (PR Newswire)
Jul-21-23 08:00AM	AcelRx Pharmaceuticals Announces Closing of Previously Announced Private Placement Priced At-The-Market Under Nasdaq Rules (PR Newswire)
Jul-18-23 08:00AM	AcelRx Pharmaceuticals Announces $10 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules (PR Newswire)
May-10-23 06:25PM	AcelRx Pharmaceuticals (ACRX) Reports Break-Even Earnings for Q1 (Zacks) +10.88%
05:18PM	AcelRx Pharmaceuticals: Q1 Earnings Snapshot (AP Finance)
04:05PM	AcelRx Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update (PR Newswire)
May-04-23 10:00AM	Earnings Preview: Crinetics Pharmaceuticals, Inc. (CRNX) Q1 Earnings Expected to Decline (Zacks)
May-03-23 10:00AM	AcelRx Pharmaceuticals (ACRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Apr-27-23 04:05PM	AcelRx to Host First Quarter 2023 Financial Results Call and Webcast on May 10, 2023 (PR Newswire)
Apr-05-23 08:30AM	AcelRx Pharmaceuticals Announces Closing of Divestment of DSUVIA® to Alora Pharmaceuticals (PR Newswire)
Apr-04-23 12:30PM	AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-30-23 06:15PM	AcelRx Pharmaceuticals (ACRX) Reports Q4 Loss, Lags Revenue Estimates (Zacks) -6.00%
04:05PM	AcelRx Pharmaceuticals Reports Full Year and Fourth Quarter 2022 Financial Results and Provides Corporate Update (PR Newswire)
Mar-29-23 10:13AM	12 Cheap Healthcare Stocks to Buy in 2023 (Insider Monkey)
Mar-21-23 04:05PM	AcelRx to Host Full Year and Fourth Quarter 2022 Financial Results Call and Webcast on March 30, 2023 (PR Newswire) +18.10% +5.68%
Mar-14-23 08:30AM	AcelRx Pharmaceuticals Announces Divestment of DSUVIA® to Alora Pharmaceuticals (PR Newswire) -21.05%
Mar-01-23 08:30AM	AcelRx Pharmaceuticals Announces Peer-Reviewed Publication On the Use of DSUVIA® For In-Office Rhinology Procedures (PR Newswire) -7.04%
Dec-29-22 06:02AM	AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Q3 2022 Earnings Call Transcript (Insider Monkey) +7.58%
Dec-27-22 08:30AM	AcelRx Announces $7.5 Million Registered Direct Offering of Common Stock and Warrants to Purchase Common Stock (PR Newswire)
Dec-19-22 08:17AM	10 Cheapest Stocks With Biggest Upside (Insider Monkey) -7.95%
Dec-08-22 08:30AM	AcelRx Pharmaceuticals Announces European Peer-Reviewed Publication Supporting the Benefits of Sublingual Sufentanil Tablets For Post-Operative Pain Management in the Journal of Clinical Medicine (PR Newswire)
Nov-17-22 05:17AM	AcelRx Pharmaceuticals Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag (Simply Wall St.)
Nov-14-22 05:15PM	AcelRx Pharmaceuticals (ACRX) Reports Q3 Loss, Misses Revenue Estimates (Zacks) +17.96%
04:01PM	AcelRx Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update (PR Newswire)
Nov-03-22 08:30AM	AcelRx to Host Third Quarter 2022 Financial Results Call and Webcast on November 14, 2022 (PR Newswire)
Oct-31-22 08:30AM	AcelRx Pharmaceuticals Announces Presentation of a Large Cohort of Complex Plastic Surgery Procedures Performed with DSUVIA at Plastic Surgery The Meeting 2022 (PR Newswire)
Oct-27-22 08:30AM	AcelRx Pharmaceuticals Announces the European Launch of DZUVEO by its Partner, Aguettant (PR Newswire) -12.47%
Oct-26-22 08:30AM	AcelRx Pharmaceuticals Announces Presentation of Investigator-Initiated Trial Results Comparing AcelRx's Sufentanil Sublingual Tablet (SST) Versus Intravenous Opioids for Postoperative Pain at the ANESTHESIOLOGY® Annual Meeting 2022 (PR Newswire) -12.81%
Oct-25-22 04:42PM	AcelRx Pharmaceuticals Announces Reverse Stock Split (PR Newswire)
08:30AM	AcelRx Pharmaceuticals Announces ANESTHESIOLOGY® 2022 Annual Meeting Presentation on DSUVIA® for Battlefield Analgesia by the Uniformed Services University of the Health Sciences (PR Newswire)
Sep-06-22 04:30PM	AcelRx Pharmaceuticals to Participate in the H.C. Wainwright Annual Investment Conference (PR Newswire) -7.32% +5.74%
Aug-25-22 08:30AM	AcelRx Pharmaceuticals Announces a Second Abstract on DSUVIA® Accepted for Presentation at the ANESTHESIOLOGY® 2022 Annual Meeting (PR Newswire)
Aug-11-22 05:35PM	AcelRx Pharmaceuticals (ACRX) Reports Q2 Loss, Misses Revenue Estimates (Zacks) +33.02% -13.63%
04:01PM	AcelRx Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update (PR Newswire)
08:30AM	AcelRx Pharmaceuticals Announces Abstract Acceptance for Podium Presentation at Plastic Surgery: The Meeting 2022 (PR Newswire)
Aug-10-22 08:30AM	AcelRx Pharmaceuticals Announces Abstract Acceptance for Podium Presentation at the ANESTHESIOLOGY® 2022 Annual Meeting (PR Newswire)
Jul-28-22 04:50PM	AcelRx to Host Second Quarter 2022 Financial Results Call and Webcast on August 11, 2022 (PR Newswire)
Jul-08-22 06:28AM	AcelRx Pharmaceuticals (NASDAQ:ACRX) shareholders are up 44% this past week, but still in the red over the last three years (Simply Wall St.) -13.71%
May-20-22 12:49PM	AcelRx Pharmaceuticals to Participate in the H.C. Wainwright Global Investment Conference (PR Newswire) -11.83%
May-19-22 11:56AM	Why AcelRx Pharma Shares Are Trading Higher Today? (Benzinga) +27.63%
08:30AM	AcelRx Pharmaceuticals Provides Update on Reduced FDA REMS Requirements Related to DSUVIA® (PR Newswire)
May-16-22 08:45AM	AcelRx Pharmaceuticals (ACRX) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:30AM	AcelRx Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update (PR Newswire)
May-12-22 05:35PM	Acutus Medical, Inc. (AFIB) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +17.66%
May-10-22 05:35PM	Organogenesis (ORGO) Q1 Earnings Lag Estimates (Zacks) -10.10%
08:30AM	AcelRx Pharmaceuticals Announces Publication of Results from an Investigator-Initiated Trial on Sufentanil Sublingual Tablet (SST) Compared to Standard Intravenous Opioids during Plastic Surgery Procedures Performed under General Anesthesia (PR Newswire)
May-09-22 07:30PM	AcelRx to Host First Quarter 2022 Financial Results Call and Webcast on May 16, 2022 (PR Newswire) -13.47%
Apr-27-22 08:00AM	AcelRx Hosting Key Opinion Leader Webinar on Niyad Nafamostat Program (GlobeNewswire)
Apr-25-22 08:30AM	Minimal Side Effects and Short Recovery Time Reported for DSUVIA®-Treated Patients: Plastic Surgery Podium Presentation at The Aesthetic Meeting 2022 (PR Newswire)
Apr-21-22 08:30AM	AcelRx Pharmaceuticals Announces Upcoming Podium Presentation on Use of DSUVIA® for Plastic Surgery Procedures at The Aesthetic Meeting 2022 (PR Newswire) -8.00%
Mar-31-22 04:10PM	AcelRx Pharmaceuticals Announces Publication of Results from a Clinical Study Assessing Use of Sufentanil Sublingual Tablet for Painful Radiofrequency Microneedling Procedures (PR Newswire)
Mar-29-22 01:08PM	AcelRx Pharmaceuticals Announces Publication of Clinical Data Finding Potential Benefits of Nafamostat Compared to Regional Citrate for Anticoagulation of the Dialysis Circuit (PR Newswire) -6.87%
Mar-10-22 05:15PM	AcelRx Pharmaceuticals (ACRX) Reports Q4 Loss, Misses Revenue Estimates (Zacks) -20.63%
04:01PM	AcelRx Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results (PR Newswire)
Mar-03-22 04:05PM	AcelRx to Host Fourth Quarter and Full Year 2021 Financial Results Call and Webcast on March 10, 2022 (PR Newswire) -7.14%
Feb-01-22 08:30AM	AcelRx Pharmaceuticals Announces Publication of Clinical Data on the Use of Sufentanil Sublingual Tablet during Awake Plastic Surgery Procedures (PR Newswire)
Jan-31-22 04:24AM	When Will AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Breakeven? (Simply Wall St.) +11.77%
Jan-27-22 01:38PM	Edmonds Duncan Registered Investment Advisors, LLC Buys VanEck Vectors Semiconductor ETF, ... (GuruFocus.com) -8.64%
08:30AM	AcelRx Pharmaceuticals Announces Publication of an Article Highlighting the Utility of the Sufentanil Sublingual Tablet in Pain Medicine Procedures (PR Newswire)
Jan-12-22 08:30AM	AcelRx Pharmaceuticals Announces Publication of an Editorial by an Internationally Recognized Leader in Opioid-Sparing Surgery Highlighting the Potential Advantages of the Sufentanil Sublingual Tablet in Joint Replacement Surgery (PR Newswire) -5.53%
Jan-10-22 08:30AM	AcelRx Pharmaceuticals Announces the Closing of its Acquisition of Lowell Therapeutics (PR Newswire)
Dec-23-21 08:05AM	Femasys Inc. to Participate in Upcoming January Investor Conferences (GlobeNewswire)
Dec-15-21 08:30AM	AcelRx Pharmaceuticals Announces Publication of Clinical Data Showing Reduced Hospital Length of Stay and Reduced Opioid Utilization with Use of Sublingual Sufentanil in Total Joint Replacement Surgery (PR Newswire)

Talphera, Inc. engages in the development and commercialization of therapies used in medically supervised settings. The firm's portfolio includes DSUVIA, DZUVEO, Zalviso, ARX-02 and ARX-03. The company was founded by Thomas A. Schreck and Pamela Pierce Palmer on July 13, 2005 and is headquartered in San Mateo, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Angotti Vincent J.	CHIEF EXECUTIVE OFFICER	Dec 05 '24	Buy	0.64	5,000	3,200	208,066	Dec 06 06:05 AM
ASADORIAN RAFFI	Chief Financial Officer	Dec 02 '24	Sale	0.77	155	119	37,578	Dec 02 04:22 PM
Angotti Vincent J.	CHIEF EXECUTIVE OFFICER	Nov 27 '24	Buy	0.73	5,000	3,650	203,066	Dec 02 04:20 PM
ASADORIAN RAFFI	Officer	Dec 02 '24	Proposed Sale	0.69	155	107		Dec 02 12:31 PM
Angotti Vincent J.	CHIEF EXECUTIVE OFFICER	Aug 30 '24	Buy	1.05	7,260	7,598	198,066	Sep 03 04:22 PM
Angotti Vincent J.	CHIEF EXECUTIVE OFFICER	Jun 13 '24	Buy	0.97	4,570	4,438	179,502	Jun 14 05:19 PM
Angotti Vincent J.	CHIEF EXECUTIVE OFFICER	Jun 12 '24	Buy	0.97	4,126	4,013	174,932	Jun 14 05:19 PM
Angotti Vincent J.	CHIEF EXECUTIVE OFFICER	Jun 14 '24	Buy	1.08	1,304	1,404	180,806	Jun 14 05:19 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TLPH

Talphera Inc

Upgrade your FINVIZ experience